Abstract
The efficacy and safety of alprostadil were investigated in this open-label study of 105 men with various etiologies of erectile dysfunction (ED). Initially, patients received an intracavernous injection of alprostadil 2.5 μg, with subsequent increases in dose until a full erection (lasting 30 to 60 minutes) was achieved or a dose of 40 μg was reached. Ninety-eight (96.1%) of the 102 patients who completed the study achieved a full erection. More patients with psychogenic ED (46.5%) versus those with vascular ED (4.0%) responded to a 2.5-μg dose. Penile pain was reported by 12 (11.4%) of 105 patients. There were no reports of erections lasting longer than 4 hours, penile hematoma, or penile abnormalities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
